All In Biotech

Drug Trial Radar · NCT07751848

A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

417

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Aug 25, 2028

Study completion Aug 30, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to describe clinical outcomes, with focus on remission, achieved with use of anifrolumab participants with SLE on standard-of-care (as recommended by 2025 China SLE guidelines). Further, it aims to describe outcomes alongside a systematic approach to glucocorticoid (GC) tapering, in terms of effectively minimising GC use, as well as discontinuing GC use, thereby reducing GC exposure.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • AnifrolumabDrug

    The study intervention, anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes from Week 0 to Week 48 for a total of 13 doses. Each dose must be at least 14 days apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients who achieve DORIS remission at week 52Time frame: Week 52

Locations

74 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Bengbu, China · Recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Changde, China · Not yet recruiting

  • Research Site

    Changlexi, China · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Dalian, China · Not yet recruiting

  • Research Site

    Fuzhou, China · Not yet recruiting

  • Research Site

    Guangdong Province, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Not yet recruiting

  • Research Site

    Hangzhou, China · Not yet recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Harbin, China · Not yet recruiting

  • Research Site

    Hefei, China · Recruiting

  • Research Site

    Hengyang, China · Not yet recruiting

  • Research Site

    Hohhot, China · Not yet recruiting

  • Research Site

    Jinan, China · Not yet recruiting

  • Research Site

    Kunming, China · Not yet recruiting

  • Research Site

    Lanzhou, China · Recruiting

  • Research Site

    Linyi, China · Not yet recruiting

  • Research Site

    Luoyang, China · Recruiting

  • Research Site

    Luzhou, China · Not yet recruiting

  • Research Site

    Nanchang, China · Not yet recruiting

  • Research Site

    Nanchong, China · Recruiting

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.